All Studies Meta Analysis Recent:

A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference

Marcec et al., Journal of Infection, doi:10.1016/j.jinf.2022.11.011

Nov 2022

Post
Facebook

Source PDF All Meta

Fluvoxamine

26th treatment shown to reduce risk in November 2021

^*, now known with p = 0.00014 from 21 studies, recognized in 3 countries.

Lower risk for mortality, hospitalization, progression, recovery, and cases.

No treatment is 100% effective. Protocols combine complementary and synergistic treatments. ^* >10% efficacy in meta analysis with ≥3 clinical studies.

4,000+ studies for 60+ treatments. c19early.org

Meta analysis of 7 fluvoxamine outpatient studies showing significantly lower hospitalization with treatment.

6 meta analyses show significant improvements with fluvoxamine for mortality Deng, hospitalization Deng, Deng (B), Lee, Lu, Marcec, and severity Nakhaee.

Currently there are 21 fluvoxamine for COVID-19 studies, showing 43% lower mortality [12‑62%], 42% lower ventilation [-151‑86%], 10% higher ICU admission [-72‑326%], 51% lower hospitalization [8‑73%], and 27% fewer cases [18‑35%].

1. Deng et al., Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: A systematic review and meta-analysis, Clinical Microbiology and Infection, doi:10.1016/j.cmi.2023.01.010.clinicalmicrobiologyandinfection.com, doi.org.

2. Deng (B) et al., Evaluating fluvoxamine for the outpatient treatment of COVID‐19: A systematic review and meta‐analysis, Reviews in Medical Virology, doi:10.1002/rmv.2501.wiley.com, doi.org.

3. Lee et al., Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis, JAMA Network Open, doi:10.1001/jamanetworkopen.2022.6269.jamanetwork.com, doi.org.

4. Lu et al., Effect of fluvoxamine on outcomes of nonhospitalized patients with COVID-19: A systematic review and meta-analysis, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.10.010.sciencedirect.com, doi.org.

5. Marcec et al., A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference, Journal of Infection, doi:10.1016/j.jinf.2022.11.011.sciencedirect.com, doi.org.

6. Nakhaee et al., The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis, PLOS ONE, doi:10.1371/journal.pone.0267423.plos.org, doi.org.

Important missing comments or errors? Let us know.

risk of hospitalization, 43.0% lower, RR 0.57, p = 0.03.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Marcec et al., 17 Nov 2022, peer-reviewed, 3 authors. Contact: robert.likic@mef.hr, rlikic@kbc-zagreb.hr.

This Paper Fluvoxamine All

A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference

Robert Marcec, Vinko Michael Dodig, MD Robert Likic

Journal of Infection, doi:10.1016/j.jinf.2022.11.011

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

Cheema, Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients: A systematic review and meta-analysis, J. Infect

Lee, Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis, JAMA Netw. Open

Mccarthy, Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial, doi:10.1101/2022.10.17.22281178

Reis, Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial, Lancet Glob. Heal

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0